SC golimumab

Phase 3Monoclonal antibody

Merck & Co.

SC golimumab is one of 66 biologic programs targeting Rheumatoid Arthritis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisActive, not recruiting

Ulcerative ColitisActive, not recruiting

Rheumatoid ArthritisPhase 3

Active, not recruiting

Ulcerative ColitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Rituxan

Roche

Preclinical

61 2

Cimzia

UCB

Preclinical

30 3

Simponi

Johnson & Johnson

Preclinical

19 4

Enbrel

IImmunex

Preclinical

64 5

Remicade

OOrganon and Co

Preclinical

43 6

SC golimumab

Merck & Co.

Phase 3

1 7

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 8

Ilaris

Novartis

Preclinical

3 9

Celexa

AbbVie

Preclinical

1 10

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 3Active, not recruiting

Ulcerative Colitis

NCT06052059

Q4 2029

Phase 3Recruiting

Crohn's Disease

NCT06430801

Clinical

Trials by Indication[1]

Ulcerative Colitis1 trial

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06052059·1,020 enrolled

Rheumatoid Arthritis1 trial

Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00975130·3,366 enrolled

Crohn's Disease1 trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Moderately to Severely Active Crohn's Disease

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06430801·1,200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SC golimumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SC golimumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SC golimumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

SC golimumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Q4 2029

Trials by Indication[1]

Ulcerative Colitis1 trial

Rheumatoid Arthritis1 trial

Crohn's Disease1 trial

References

Drug Info

Quick Facts

Related News